Several
studies have assessed the immunogenicity of the
Urabe strain mumps vaccine in developing countries.
Among seronegative children who received
Urabe strain mumps vaccine at 9 months of age,
99% seroconverted in Brazil (65), 98% in South
Africa (66), and 75% in India